Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MIF | P14174 | 10/20 | 0.49 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.48 |
| ▸ | CYP2E1 | P05181 | 1/20 | 0.48 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.48 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.48 |
| ▸ | CYP2A13 | Q16696 | 1/20 | 0.48 |
| ▸ | EPAS1 | Q99814 | 1/20 | 0.48 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.44 |
| ▸ | CALM1 | P0DP23 | 3/20 | 0.42 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | DAO | P14920 | 1/20 | 0.38 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1847534 | 0.81 | CYP19A1 (0.44) | CYP19A1CALM1AKR1B1ALDH1A1DAO | |
| SCHEMBL4701206 | 0.81 | MIF (0.68) | MIFTRPA1CYP2E1CYP2A6HIF1A | |
| SCHEMBL13623241 | 0.80 | MIF (0.64) | MIFTRPA1CYP2E1CYP2A6HIF1A | |
| SCHEMBL9491787 | 0.75 | CYP19A1 (0.68) | CYP19A1CALM1AKR1B1ALDH1A1DAO | |
| SCHEMBL1973945 | 0.74 | ATM (0.54) | MIFTRPA1CYP2E1CYP2A6HIF1A | |
| SCHEMBL18179858 | 0.72 | CYP19A1 (0.46) | CYP19A1CALM1AKR1B1ALDH1A1DAO | |
| SCHEMBL10566112 | 0.71 | MIF (0.64) | MIFTRPA1CYP2E1CYP2A6HIF1A | |
| SCHEMBL332410 | 0.71 | MIF (0.79) | MIFTRPA1CYP2E1CYP2A6HIF1A | |
| SCHEMBL17050033 | 0.69 | MIF (0.52) | MIFTRPA1CYP2E1CYP2A6HIF1A | |
| SCHEMBL17274310 | 0.69 | NAAA (0.63) | MIFCALM1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160009724-A1 | TRICYCLIC TRIAZOLE COMPOUNDS THAT MODULATE HSP90 ACTIVITY | SYNTA PHARMACEUTICALS CORP (US) | 2016-01-14 | — | — | US | disclosed |
| US-20160009724-A1 | TRICYCLIC TRIAZOLE COMPOUNDS THAT MODULATE HSP90 ACTIVITY | SYNTA PHARMACEUTICALS CORP (US) | 2016-01-14 | — | — | US | disclosed |
| US-20160009724-A1 | TRICYCLIC TRIAZOLE COMPOUNDS THAT MODULATE HSP90 ACTIVITY | SYNTA PHARMACEUTICALS CORP (US) | 2016-01-14 | — | — | US | disclosed |
| US-9156836-B2 | Tricyclic triazole compounds that modulate HSP90 activity | SYNTA PHARMACEUTICALS CORP. (US) | 2015-10-13 | — | — | US | disclosed |
| US-9156836-B2 | Tricyclic triazole compounds that modulate HSP90 activity | SYNTA PHARMACEUTICALS CORP. (US) | 2015-10-13 | — | — | US | disclosed |
| US-9156836-B2 | Tricyclic triazole compounds that modulate HSP90 activity | SYNTA PHARMACEUTICALS CORP. (US) | 2015-10-13 | — | — | US | disclosed |
| US-20110152310-A1 | TRICYCLIC TRIAZOLE COMPOUNDS THAT MODULATE HSP90 ACTIVITY | SYNTA PHARMACEUTICALS CORP. | 2011-06-23 | — | — | US | disclosed |
| US-20110152310-A1 | TRICYCLIC TRIAZOLE COMPOUNDS THAT MODULATE HSP90 ACTIVITY | SYNTA PHARMACEUTICALS CORP. | 2011-06-23 | — | — | US | disclosed |
| US-20110152310-A1 | TRICYCLIC TRIAZOLE COMPOUNDS THAT MODULATE HSP90 ACTIVITY | SYNTA PHARMACEUTICALS CORP. | 2011-06-23 | — | — | US | disclosed |
| WO-2009139916-A1 | TRICYCLIC TRIAZOLE COMPOUNDS THAT MODULATE HSP90 ACTIVITY | SYNTA PHARMACEUTICALS CORP. (US) | 2009-11-19 | — | — | WO | disclosed |
| WO-2009139916-A1 | TRICYCLIC TRIAZOLE COMPOUNDS THAT MODULATE HSP90 ACTIVITY | SYNTA PHARMACEUTICALS CORP. (US) | 2009-11-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160009724-A1 | TRICYCLIC TRIAZOLE COMPOUNDS THAT MODULATE HSP90 ACTIVITY | HSP90AB1, CDC37, HSP90B1 | MIF 1155/4885TRPA1 4148/4885CYP2E1 1760/4885 |
| US-20110152310-A1 | TRICYCLIC TRIAZOLE COMPOUNDS THAT MODULATE HSP90 ACTIVITY | HSP90AB1, CDC37, HSP90B1 | MIF 1155/4885TRPA1 4148/4885CYP2E1 1760/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.